Evofem Biosciences, Inc. (EVFM)
| Market Cap | 1.11M |
| Revenue (ttm) | 19.36M |
| Net Income (ttm) | -8.97M |
| Shares Out | 113.36M |
| EPS (ttm) | -0.12 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,500 |
| Average Volume | 591,109 |
| Open | 0.0100 |
| Previous Close | 0.0098 |
| Day's Range | 0.0098 - 0.0100 |
| 52-Week Range | 0.0060 - 0.0290 |
| Beta | -0.74 |
| RSI | 57.49 |
| Earnings Date | Mar 3, 2025 |
About Evofem Biosciences
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women’s sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California. [Read more]
Financial Performance
Financial StatementsNews
Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics
-- Evofem's Cost to Manufacture PHEXXI will Decrease by 55% - 60% -- SAN DIEGO , March 26, 2025 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) (Evofem or the Company) today announced that it h...
Evofem Reports Fourth Consecutive Year of Net Sales Growth
-- 2024 Net Sales Increased 6% to $19.4 Million -- -- Total Operating Expense Reduced 27% from 2023 Levels, Excluding Non-cash Amortization Expense -- -- Sales and Marketing Expense as a Percentage...
Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved Product
WARRINGTON, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating biotech...
Evofem Strengthens SOLOSEC Intellectual Property with New U.S. Patent from USPTO
-- Allowed Patent Extends SOLOSEC IP to 2040 with Broad Claims that are Orange Book-listable -- SAN DIEGO , Feb. 13, 2025 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced that t...
Evofem Biosciences Announces Financial Results for the Third Quarter of 2024
— Improved loss from operations by 31% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — — Forged commercial...
Evofem Secures Investor Support for Proposed Merger through Voting Agreements
SAN DIEGO , Nov. 6, 2024 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) ("Evofem" or the "Company") today announced it has secured voting agreements with certain of its Series E-1 stockholders...
Evofem Biosciences Addresses the Impact of GLP-1 Medications on Oral Contraceptive Absorption and Introduces Phexxi as a Non-Oral Solution
SAN DIEGO , Aug. 20, 2024 /PRNewswire/ -- As the popularity of GLP-1 receptor agonists continues to surge in the treatment of obesity and type 2 diabetes, Evofem Biosciences, Inc. (OTCQB: EVFM) is rai...
Evofem Biosciences GAAP EPS of $0.00, revenue of $4.16M
Evofem Biosciences Announces Financial Results for the Second Quarter of 2024
— Improved loss from operations by 81% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — — Forged ex-U.S. co...
Evofem Biosciences to Present at the OTCQB Venture Virtual Investor Conference on August 1st
Live moderated video webcast with Evofem management on Thursday, August 1 at 10:30am ET Live moderated video webcast with Evofem management on Thursday, August 1 at 10:30am ET
Evofem Signs Phexxi® License Agreement for Middle East with Pharma 1
— Pharma 1 anticipates filing UAE regulatory submission for Phexxi as a hormone-free contraceptive in Q3 2024 — — UAE contraceptive drug market is projected to reach $185.1 million by 2030 — SAN DIE...
Lupin Divests U.S. Commercial Women's Health Specialty Business to Evofem, including SOLOSEC
MUMBAI, India and NAPLES, Fla. and SAN DIEGO , July 15, 2024 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) announced today...
Hello Alpha Partners with Evofem to Offer Phexxi® as a Hormone-Free Contraception Solution on its Platform for Women's Healthcare
— Leading telemedicine company expands offering with hormone-free birth control as GLP-1 medication usage increases — — Hello Alpha partnership boosts awareness of and access to Phexxi for millions of...
Evofem Announces Issuance of New U.S. Patent Covering Phexxi Composition of Matter
-- Issuance of U.S. Patent No. 11,992,472 Further Strengthens Evofem's Intellectual Patent Portfolio -- -- Newly issued patent is Evofem's fifth covering Hormone-Free "In the Moment" Contraceptive Phe...
Evofem Biosciences Announces Financial Results for the First Quarter of 2024
SAN DIEGO , May 15, 2024 /PRNewswire/ -- The company behind the hormone-free contraceptive Phexxi® (lactic acid, citric acid and potassium bitartrate), Evofem Biosciences, Inc. ("Evofem" or "the Compa...
Evofem Strengthens Phexxi Intellectual Property with New Composition of Matter Patent From USPTO
-- Application allowed with broad method claims that are Orange Book-listable -- -- Once issued, this will be Evofem's fifth patent covering Hormone-Free "In the Moment" Contraceptive Phexxi in the Un...
Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023
-- Third Consecutive Year of Phexxi Net Sales Growth -- -- Total Operating Expense Reduced 64% from 2022 Levels -- -- Sales and marketing expense as a percentage of net sales was 54% for the fourth ...
Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI with Medi-Cal
— Medi-Cal serves more than 15.4 million Californians — — 7.4% improvement in Phexxi rebate to take effect July 1, 2024 — SAN DIEGO , March 20, 2024 /PRNewswire/ -- Commercial-stage women's health inn...
For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy
-- New weight loss drugs like Ozempic, Wegovy and Zepboundmay make oral birth control pills less effective at certain points -- SAN DIEGO , March 7, 2024 /PRNewswire/ -- Use of GLP-1 receptor agonists...
Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023
Evofem Delivers Third Consecutive Year of Phexxi Net Sales Growth Total Operating Expense Reduced More Than 60% from 2022 Levels SAN DIEGO , Feb. 1, 2024 /PRNewswire/ -- Evofem Biosciences, Inc. (OT...
Washington State HCA Removes Prior Authorization for Hormone-Free "In the Moment" Contraceptive PHEXXI Ahead of Huskies vs. Wolverines Championship Game
— Removal of Prior Authorization Upgrades Phexxi Coverage for Nearly 1.8 Million Washington Lives Across All Medicaid Plans — — Fans Encouraged to Plan for Victory, Prevent Unintended Pregnancy — S...
EVOFEM BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Evofem Biosciences, Inc. - EVFM
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Evofem Bioscienc...
Shareholder Alert: Ademi LLP investigates whether Evofem Biosciences, Inc. has obtained a Fair Price in its transaction with Aditxt
MILWAUKEE , Dec. 12, 2023 /PRNewswire/ -- Ademi LLP is investigating Evofem (OTCQB: EVFM) for possible breaches of fiduciary duty and other violations of law in its transaction with Aditxt. Click here...
EVFM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Evofem Biosciences, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Evofem Biosciences, Inc. (OTCQB: EVFM) and Aditxt, Inc. is fair to Evofem shareholders....
Evofem Biosciences Announces Financial Results for the Third Quarter of 2023
— On track to achieve third consecutive year of revenue growth – — Third consecutive quarter of favorable sales and marketing expense as a percentage of net sales — — Reduced loss from operations by 8...